Table 1.
Sample Characteristics – Sociodemographic and Injury-specific Covariates by Race
| Under Age 65 | Over Age 65 | |||||
|---|---|---|---|---|---|---|
| White 4,161 (76.4%) |
Black 1,286 (23.6%) |
P-value | White 1,845 (88.1%) |
Black 249 (11.9%) |
P-value | |
| Sex | 0.40 | 0.68 | ||||
| Male | 3,034 (72.9%) | 953 (74.1%) | 878 (47.6%) | 115 (46.2%) | ||
| Female | 1,127 (27.1%) | 333 (25.9%) | 967 (52.4%) | 134 (53.82%) | ||
| Median Income | <.001 | <.001 | ||||
| less than $48,519 | 655 (16.5%) | 777 (62.5%) | 252 (14.2%) | 149 (62.6%) | ||
| $48,520–$65,062 | 1,141 (28.7%) | 211 (16.9%) | 420 (23.6%) | 30 (12.6%) | ||
| $65,063–$85,588 | 1,068 (26.9%) | 148 (11.9%) | 560 (31.5%) | 36 (15.1%) | ||
| greater than $85,589 | 1,111 (29.9%) | 108 (8.7%) | 548 (30.8%) | 23 (9.7%) | ||
| Previous Trauma | <.001 | 0.61 | ||||
| No | 3,818 (91.8%) | 1,139 (88.6%) | 1,769 (95.9%) | 237 (95.2%) | ||
| Yes | 343 (8.2%) | 147 (11.4%) | 76 (4.1%) | 12 (4.8%) | ||
| Mechanism of Fall | <.001 | <.001 | ||||
| Same level | 453 (10.9%) | 142 (11.1%) | 229 (12.4%) | 32 (12.9%) | ||
| Stairs | 818 (19.7%) | 353 (27.5%) | 564 (30.6%) | 105 (42.2%) | ||
| Height | 2,267 (54.5%) | 585 (45.5%) | 449 (24.3%) | 55 (22.1%) | ||
| Unspecified | 623 (14.9%) | 205 (15.9%) | 603 (32.7%) | 57 (22.9%) | ||
| Hip Fracture | 0.08 | 0.18 | ||||
| No | 4,086 (98.2%) | 1,272 (98.9%) | 1,759 (95.3%) | 242 (97.2%) | ||
| Yes | 75 (1.8%) | 14 (1.1%) | 86 (4.7%) | 7 (2.8%) | ||
| ISS | 0.53 | 0.07 | ||||
| Missing | 188 (4.5%) | 69 (5.4%) | 30 (1.6%) | 9 (3.6%) | ||
| 1–8 | 2,228 (53.5%) | 709 (55.1%) | 795 (43.9%) | 117 (46.9%) | ||
| 9–15 | 888 (21.3%) | 263 (20.5%) | 447 (24.2%) | 53 (21.3%) | ||
| 16–24 | 525 (12.62%) | 144 (11.2%) | 340 (18.4%) | 41 (16.4%) | ||
| 25–49 | 316 (7.6%) | 95 (7.4%) | 226 (12.3%) | 26 (10.4%) | ||
| 50+ | 16 (0.4%) | 6 (0.5%) | 7 (0.4%) | 3 (1.2%) | ||
| BAC | <.001 | 0.003 | ||||
| Negative | 2,985 (71.7%) | 784 (60.9%) | 1,497 (81.1%) | 183 (73.5%) | ||
| <80mg/dL | 118 (2.8%) | 58 (4.5%) | 37 (2.1%) | 2 (0.8%) | ||
| >=80mg/dL | 794 (19.1%) | 335 (26.1%) | 139 (7.5%) | 32 (12.9%) | ||
| Unknown | 264 (6.3%) | 109 (8.5%) | 172 (9.3%) | 32 (12.9%) | ||
| Urine Drug Screen | <.001 | 0.25 | ||||
| Negative | 1,171 (28.1%) | 351 (27.9%) | 626 (33.9%) | 97 (38.9%) | ||
| Positive | 818 (19.7%) | 303 (20.6%) | 190 (10.3%) | 21 (8.4%) | ||
| Unknown | 2,172 (52.2%) | 632 (49.1%) | 1,029 (55.8%) | 131 (52.6%) | ||
| Comorbidities* | ||||||
| Cerebrovascular | 48 (1.2%) | 28 (2.2%) | 0.006 | 173 (9.4%) | 22 (8.8%) | 0.78 |
| Hypertension | 599 (14.4%) | 222 (17.26%) | 0.01 | 940 (50.9%) | 139 (55.8%) | 0.15 |
| Diabetes | 219 (5.3%) | 87 (6.8%) | 0.04 | 311 (16.9%) | 53 (21.3%) | 0.08 |
| Chronic Renal Failure | 11 (0.3%) | 9 (0.7%) | 0.02 | 22 (1.2%) | 5 (2.0%) | 0.28 |
| COPD | 46 (1.1%) | 6 (0.5%) | 0.04 | 98 (5.3%) | 5 (2.0%) | 0.02 |
| In-hospital Mortality | 0.17 | 0.49 | ||||
| No | 4,065 (97.7%) | 1,248 (97.1%) | 1,631 (88.5%) | 224 (89.9%) | ||
| Yes | 95 (2.3%) | 38 (2.9%) | 212 (11.5%) | 25 (10.1%) | ||
*
The number of patients with a comorbidity is listed with p-value comparing the number without a comorbidity by race